- Engaged with RNAi biotech company at invitation of principal shareholders
- Developed IM and divestment strategy to realise exit for investors
- Divested primary technology platform to Ambion, who were the principal distributor for the company, acquired in turn by ABI, thereby returning some capital to investors and providing company a base for continued operations a final sale efforts.
- Developed second strategic alliance programme for company for joint R&D programme and ultimate equity acquisition options
- Developed and implemented strategy for exit of investors from remaining company
Return to all case studies